Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer

Kenneth M. Wong¹, Theodore Scott Nowicki², Carmelo Puccio³, Tauseef Ahmed³, Raj Tiwari², Jan Geliebter², Augustine Moscatello⁴

¹Department of Otolaryngology—Head and Neck Surgery, New York Eye and Ear Infirmary, New York, USA; ²Department of Microbiology and Immunology, New York Medical College, Valhalla, USA; ³Department of Medical Oncology, Westchester Medical Center, Valhalla, USA; ⁴Department of Otolaryngology—Head and Neck Surgery, Westchester Medical Center, Valhalla, USA.
Email: kwong@nyee.edu

Received February 28th, 2012; revised March 31st, 2012; accepted April 15th, 2012

ABSTRACT

Background: Anaplastic thyroid cancer (ATC), while rare, carries a uniformly poor prognosis. Current treatment includes surgery when possible, radiotherapy, and chemotherapy. Multiple chemotherapeutic agents are in the process of clinical testing, and promising agents include those in the tyrosine kinase inhibitor family. Our patient represents a novel case of ATC treated with sunitinib, one such tyrosine kinase inhibitor.

Methods/Results: We utilized the experimental sunitinib in conjunction with radiation therapy to treat a patient with aggressive ATC in whom curative resection was unable to be achieved due to carotid sheath and tracheal involvement. The patient had marked clinical response and sustained stable disease for 8 months, which coincides with reported data regarding sunitinib to treat other thyroid malignancies.

Conclusion: Our case illustrates the efficacy of sunitinib therapy as a possible adjunct in the treatment of ATC.

Keywords: Sunitinib; Anaplastic Thyroid Cancer; Tyrosine Kinase Inhibitor; Chemotherapy; ATC

1. Introduction

Anaplastic thyroid cancer (ATC) is the least common thyroid malignancy, but carries an extremely poor prognosis. The female to male ratio is 5:1 and peak incidence is in the sixth and seventh decade of life [1]. Median life expectancy after diagnosis is only 3 - 9 months, with two year survival rates at only 10% - 15% [2]. Presenting symptoms are usually a rapidly enlarging neck mass with associated symptoms of dyspnea, hoarseness, or dysphagia. ATC has a propensity for rapid progression; approximately 20% - 50% of patients have distant metastasis at the time of diagnosis, and 25% develop new metastasis during the course of the disease [3]. Although not standardized, management of ATC ideally involves multimodality treatment (consisting of surgery, radiotherapy, and chemotherapy) to maximize clinical outcome, as such management paradigms have been shown to improve survival times [4]. Additionally, multiple studies have shown that performing curative resection confers increased one-year survival rates, as well as increased overall survival times [3,5].

Multiple chemotherapeutic agents have been used in the treatment of ATC, and many more are in the process of clinical testing. One such experimental agent is sunitinib (SU011248, Sutent), which is a tyrosine kinase inhibitor with activities against vascular endothelial growth factor receptor (VEGFR) types 1 and 2, platelet-derived growth factor receptor (PDGFR) alpha and beta, c-KIT, and RET. It is FDA-approved for use against renal cell carcinoma and imatinib-refractory gastrointestinal stromal tumors, but its use has been broadened as the molecular biology of thyroid cancer becomes better understood [6]. Several phase II trials involving sunitinib are being conducted on patients with medullary thyroid cancer (MTC) and well differentiated thyroid cancer (WDTC). Preliminary results published thus far have been promising: sunitinib treatment has been shown to increase partial response rates and duration of stable disease in MTC and WDTC patients alike [7-9]. There have also been multiple individual case reports of WDTC patients with prolonged disease stabilization after treatment with sunitinib, even in the face of distant metastasis [10-12].

However, there are no published reports dealing with the use of sunitinib to improve the clinical course of ATC. Here we report on a patient with aggressive ATC who was treated with sunitinib, which resulted in a marked...
Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer

2. Case Report

The patient is a 54-year-old female who was transferred to Westchester Medical Center in May 2011 with increasing respiratory distress, stridor, shortness of breath, and a rapidly enlarging neck mass during a six week period. She complained of difficulty sleeping in the left lateral decubitus position and had dysphagia for solids. Past medical history was significant for Lyme disease and anxiety. The patient is a current smoker with 15 pack/year history and denied alcohol and intravenous drug use. She denied exposure of external radiation to the neck or radiotherapy treatment in the past. Physical exam revealed a large approximately 6 × 6 cm firm mass in the central neck with extensive bilateral cervical lymphadenopathy greater on the right than the left. Computed tomography (CT) scan of the neck revealed a large lesion arising from the thyroid bed, with tracheal deviation to the left, extensive lymphadenopathy (right greater than left) with compression of right internal jugular vein, and large mass abutting the right carotid artery (Figure 1). CT of the chest/abdomen/pelvis did not reveal any evidence of metastatic disease. Fine needle aspiration performed from the referral hospital was inconclusive, but suggestive of medullary thyroid cancer.

The patient was taken to the operating room, where a tracheotomy with subtotal thyroidectomy was performed. Intraoperatively, there was gross disease involving the right carotid sheath and approximately 3 cm of tracheal wall invasion. Final pathological diagnosis was poorly differentiated thyroid carcinoma, 25% anaplastic component, with spindle and giant cells, and a minor component of papillary columnar cell carcinoma. Figure 2 shows post-surgical changes prior to radiotherapy and chemotherapy. The patient underwent radiation therapy and received a total dose of 5400 cGy to the thyroid bed and bilateral necks. She also received one cycle of sunitinib malate 50 mg daily for four weeks on/two weeks off beginning May 2011. Complications related to sunitinib therapy experienced by our patient included hand-foot syndrome. She developed a rash on her wrists and plantar surface of her foot, which was treated with Bacitracin and triamcinolone cream. The nadir for her white blood cell count and platelets during treatment was 2.6 × 10^3/mm^3 and 90 × 10^3/mm^3, respectively.

Clinical response was dramatic after the first cycle of sunitinib therapy. The bilateral cervical lymphadenopathy decreased clinically and became non-palpable. Repeat CT scan of the neck after the first cycle showed marked decrease in size of cervical lymphadenopathy (Figure 3). She received subsequent cycles of chemotherapy at 37.5 mg bid and has had stable disease on that
which remain active in ATC. Several recent studies have demonstrated that the PI3K/Akt signaling pathway, which is critically important to growth and invasion in WDTC (particularly PTC), remains activated in ATC as well [18,19]. By targeting this and other pathways with specific molecular inhibitors, such as sunitinib, it may be possible to reduce these growth and invasion behaviors in ATC as well. Indeed, recent studies have demonstrated that sunitinib is able to target the PI3K/Akt signaling pathway in other malignancies, resulting in impressive reductions in cellular growth [20,21].

Our patient demonstrated a marked improvement following treatment with sunitinib. Even though curative resection of the tumor was unable to be achieved due to involvement of the carotid sheath and trachea, her prolonged state of stable disease for 8 months is comparable to the reported increased median survival in patients receiving triple modality therapy compared to chemotherapy alone or radiotherapy alone (11 months vs. 5.7 months vs. 4 months, respectively) [4]. Another important study by Haigh et al. found median survival of 43 months versus 3 months (p = 0.002) in patients receiving curative resection plus adjuvant chemoradiotherapy compared to those who underwent palliative resection and adjuvant chemoradiotherapy, respectively [5]. The addition of sunitinib in our patient likely contributed to the favorable clinical outcome of controlling disease progression or recurrence.

It is worth pointing out that the patient’s positive response to sunitinib therapy goes against a recent report by D’Agostino et al. in which sunitinib failed to exert a significant effect on ATC cell growth and proliferation in vitro [22]. However, it is possible that in vitro studies are unable to completely approximate a given ATC tumor’s behavior as it would exist within the tumor micro-environment in vivo. Indeed, another recent report by Gule et al. demonstrated that direct inhibition of VEGFR-2, a molecular target of sunitinib, was able to significantly reduce the growth of ATC cells in orthotopic mouse xenografts [23]. This paper also utilized a large number ATC cell lines which were different from those studied by D’Agostino et al., highlighting the degree of genetic diversity which can be seen between individual tumors in ATC, as well as the difficulty faced in generalizing and extrapolating data derived from cellular models of this malignancy.

4. Conclusion

While the multi-targeted tyrosine kinase inhibitor sunitinib has been shown to be efficacious in the treatment of WDTC and MTC, its role in the treatment of ATC needs to be further studied. Our patient represents the first reported case utilizing sunitinib in the treatment course of ATC under this model can occur in a widely variant manner (with differences being documented among large subsets of patients) [17]. Therefore, one novel approach to therapy is to target the molecular factors present in the supposed precursor WDTC lesions which remain active in ATC. Several recent studies have demonstrated that the PI3K/Akt signaling pathway, which is critically important to growth and invasion in WDTC (particularly PTC), remains activated in ATC as well [18,19]. By targeting this and other pathways with specific molecular inhibitors, such as sunitinib, it may be possible to reduce these growth and invasion behaviors in ATC as well. Indeed, recent studies have demonstrated that sunitinib is able to target the PI3K/Akt signaling pathway in other malignancies, resulting in impressive reductions in cellular growth [20,21].

Our patient demonstrated a marked improvement following treatment with sunitinib. Even though curative resection of the tumor was unable to be achieved due to involvement of the carotid sheath and trachea, her prolonged state of stable disease for 8 months is comparable to the reported increased median survival in patients receiving triple modality therapy compared to chemotherapy alone or radiotherapy alone (11 months vs. 5.7 months vs. 4 months, respectively) [4]. Another important study by Haigh et al. found median survival of 43 months versus 3 months (p = 0.002) in patients receiving curative resection plus adjuvant chemoradiotherapy compared to those who underwent palliative resection and adjuvant chemoradiotherapy, respectively [5]. The addition of sunitinib in our patient likely contributed to the favorable clinical outcome of controlling disease progression or recurrence.

It is worth pointing out that the patient’s positive response to sunitinib therapy goes against a recent report by D’Agostino et al. in which sunitinib failed to exert a significant effect on ATC cell growth and proliferation in vitro [22]. However, it is possible that in vitro studies are unable to completely approximate a given ATC tumor’s behavior as it would exist within the tumor micro-environment in vivo. Indeed, another recent report by Gule et al. demonstrated that direct inhibition of VEGFR-2, a molecular target of sunitinib, was able to significantly reduce the growth of ATC cells in orthotopic mouse xenografts [23]. This paper also utilized a large number ATC cell lines which were different from those studied by D’Agostino et al., highlighting the degree of genetic diversity which can be seen between individual tumors in ATC, as well as the difficulty faced in generalizing and extrapolating data derived from cellular models of this malignancy.

4. Conclusion

While the multi-targeted tyrosine kinase inhibitor sunitinib has been shown to be efficacious in the treatment of WDTC and MTC, its role in the treatment of ATC needs to be further studied. Our patient represents the first reported case utilizing sunitinib in the treatment course of
Clinical Response with Sunitinib Therapy in the Treatment of Anaplastic Thyroid Cancer

ATC. The period of 8 months with stable disease is comparable to reports in the current literature of patients undergoing similar multimodality treatment, especially considering that curative resection was not achievable. Our case illustrates the efficacy of sunitinib as an adjunct to the treatment of ATC. Further clinical trials are needed to validate and define the clinical benefit.

REFERENCES


